Viking Therapeutics Announces Annual Meeting Results
Ticker: VKTX · Form: 8-K · Filed: May 23, 2024 · CIK: 1607678
Sentiment: neutral
Topics: corporate-governance, annual-meeting, officer-changes
Related Tickers: VKTX
TL;DR
Viking Therapeutics held its annual meeting, voted on exec pay, and made board/officer changes.
AI Summary
Viking Therapeutics, Inc. announced on May 21, 2024, several key updates. The company held its Annual Meeting of Stockholders where directors were elected and a proposal regarding executive compensation was voted on. Additionally, the company appointed new officers and made changes to its board of directors.
Why It Matters
This filing details important corporate governance changes and stockholder decisions, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing annual meeting outcomes and governance changes, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
FAQ
What were the key outcomes of Viking Therapeutics' Annual Meeting of Stockholders on May 21, 2024?
The filing indicates that directors were elected, and a proposal regarding compensatory arrangements of certain officers was submitted to a vote.
Were there any changes in the company's officers or directors reported in this 8-K?
Yes, the filing notes the 'Departure of Directors or Certain Officers' and 'Election of Directors' and 'Appointment of Certain Officers'.
What is the principal executive office address for Viking Therapeutics?
The principal executive offices are located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
What is the company's telephone number?
The company's telephone number, including area code, is (858) 704-4660.
What is the filing date for this 8-K report?
The filing was made as of May 23, 2024, reporting events from May 21, 2024.
Filing Stats: 1,108 words · 4 min read · ~4 pages · Grade level 10 · Accepted 2024-05-22 19:54:54
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240521.htm (8-K) — 80KB
- 0000950170-24-063707.txt ( ) — 200KB
- vktx-20240521.xsd (EX-101.SCH) — 30KB
- vktx-20240521_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 21, 2024, the Company held the Annual Meeting. Of the 110,217,994 shares of the Company's common stock outstanding as of March 28, 2024, the record date for the Annual Meeting, 88,199,492 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 80.1% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business. At the Annual Meeting, the Company's stockholders considered five proposals, each of which is described in more detail in the Company's Proxy Statement. Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal. Proposal No. 1. To elect the following nominees as Class III directors to serve until the Company's 2027 annual meeting of stockholders or until such director's respective successor is duly elected and qualified: Director Nominee Votes For Votes Withheld Broker Non-Votes Brian Lian, Ph.D. 50,502,615 17,436,415 20,260,462 Lawson Macartney, Ph.D. 22,267,255 45,671,775 20,260,462 As a result, the Company's stockholders voted to elect Brian Lian, Ph.D. and Lawson Macartney, Ph.D. as Class III directors to serve until the Company's 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified. Proposal No. 2. To ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 87,382,144 743,579 73,767 As a result, the Company's stockholders voted to ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024. Proposal No. 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Viking Therapeutics, Inc. 2024 Equity Incentive Plan (previously filed on May 22, 2024 as Exhibit 4.2 to the Registrant's Registration Statement on Form S-8 and incorporated herein by reference). 10.2 Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan (previously filed on May 22, 2024 as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8 and incorporated herein by reference). 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viking Therapeutics, Inc. Date: May 22, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)